GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic

Congratulations to 5AM Portfolio company GlycoEra on initiation of its Phase 1A trial of GE8820, the first IgG4-selective degrader to enter clinical development. This milestone marks GlycoEra’s transition into clinical development and advances its vision for precision medicines.